AU2015205839A1 — Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
Assigned to Vertex Pharmaceuticals Inc · Expires 2015-08-13 · 11y expired
What this patent protects
PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2 DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3 METHYLPYRIDIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF Abstract A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2 difluorobenzo [d][1,3]dioxol-5-yl) cyclop…
USPTO Abstract
PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2 DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3 METHYLPYRIDIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF Abstract A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2 difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2 yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
Drugs covered by this patent
- Kalydeco (IVACAFTOR) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.